Session Coverage

Presenters will review the latest research and clinical case studies to better equip clinicians in tailoring effective cessation strategies for youth and young adults, said Frank Leone, MD, MS, FCCP.

In central sleep apnea (CSA) care, clinicians are increasingly asked to move beyond one-size-fits-all approaches and toward phenotype-driven, patient-centered care, said Timothy I. Morgenthaler, MD, FCCP.

The treatment landscape for interstitial lung diseases (ILDs) has expanded dramatically in recent years, creating new opportunities—and new challenges—for clinicians, said Sean J. Callahan, MD, FCCP.

Biologics and antialarmins are rewriting the playbook for COPD treatment and opening the field to more targeted therapies and precision medicine, said Sara Assaf, MD.

The session will guide attendees through complex pneumothorax decision-making and explore cases from the audience, said Laura Kathleen Frye, MD, FCCP.

Other major topics of discussion will include endemic infections, rare-but-deadly pulmonary pathogens, and changes in vaccine policy, said Ryan Maves, MD, FCCP.

Sessions will look at new information about patients who are receiving glucagon-like peptide-1 (GLP-1) medications and how that affects their sleep-disordered breathing, said Sherri Katz, MD, FCCP.

Emerging diagnostic algorithms and advances in therapy could transform management of alpha-1 antitrypsin deficiency, an often-overlooked genetic disease that affects the lungs and the liver, said Malik Khurram Khan, MD, FCCP.

Rheumatologic diseases can be difficult to recognize when encountered in the ICU. Missing these diagnoses can delay life-saving therapies and significantly impact patients’ outcomes, said Rami Batarseh, MD, FCCP.

CHEST 2026 Honor and Memorial Lectures will recognize individuals who have advanced work in critical care, interventional medicine, mechanical ventilation, medical education, and other areas.